Transplant Surgery »  Meet the Team »  Nephrology »  Meyeon Park, MD, MAS, FASN
Meyeon Park, MD, MAS, FASN

Meyeon Park, MD, MAS, FASN

Assistant Professor
UCSF Department of Medicine, Nephrology
Director, UCSF PKD Center of Excellence

Contact Information

Open Popup
  • Harvard College
  • Perelman School of Medicine of the University of Pennsylvania
  • Yale Internal Medicine Residency
  • UCSF Nephrology Fellowship
  • UCSF Masters of Advanced Study in Clinical Research
  • ABIM Internal Medicine
  • ABIM Nephrology
  • Cardiovascular Risk in Kidney Transplant Recipients
  • Chronic Kidney Disease Progression
  • Insulin Resistance in Pkd Patients
  • Polycystic Kidney Disease

I am a nephrologist and clinical researcher at the University of California, San Francisco. I attended Harvard College and the University of Pennsylvania School of Medicine and completed my residency in Internal Medicine at Yale-New Haven Hospital. During my clinical and research fellowship in nephrology at UCSF, I became interested in risk factors for kidney disease progression and ways to predict cardiovascular risk in subgroups of the broader CKD population. I was awarded an NIH K23 Career Development Award and a Doris Duke Charitable Foundation Clinical Scientist Development Award to develop my research program. During this time, I founded the UCSF PKD Center of Excellence, where we have unified specialists with expertise in PKD in order to provide a multi-disciplinary approach to caring for individuals with PKD and to focus on ways to improve health in both the immediate and long term.

Read Dr. Parks Biography at PKD Foundation

  • Physician Gratitude Award, National PKD Foundation, 2017
  • Clinical Scientist Development Award, Doris Duke Charitable Foundation, 2015-2018
  • Pilot for Junior Investigators in Basic and Clinical/Translational Sciences, UCSF CTSI, 2015-2016
  • Centers of Excellence in Patient Research Pilot Award, UCSF Department of Medicine, 2014-2015
  • K23 Career Development Award, NIH NIDDK, 2013-2018

Since starting my nephrology fellowship at UCSF, I have been devoted to the study of the close relationships between cardiovascular and kidney diseases. My current research focus is in kidney transplant recipients and individuals with polycystic kidney disease, and I am currently enrolling patients into observational cohorts of these conditions and characterizing them with imaging, biospecimen, and clinical data. We have both observational and interventional studies ongoing in PKD patients currently.

Most recent publications from a total of 22
  1. Park M, Maristany D, Huang D, Shlipak MG, Whooley M. Associations of TNFR1 with kidney function outcomes by age, gender, and baseline kidney function status: Data from the Heart and Soul Study. Data Brief. 2017 Oct; 14:366-370. View in PubMed
  2. Tran WC, Huynh D, Chan T, Chesla CA, Park M. Understanding barriers to medication, dietary, and lifestyle treatments prescribed in polycystic kidney disease. BMC Nephrol. 2017 Jul 05; 18(1):214. View in PubMed
  3. Park M, Maristany D, Huang D, Shlipak MG, Whooley M. Associations of tumor necrosis factor alpha receptor type 1 with kidney function decline, cardiovascular events, and mortality risk in persons with coronary artery disease: Data from the Heart and Soul Study. Atherosclerosis. 2017 Aug; 263:68-73. View in PubMed
  4. Park M, Hsu CY, Go AS, Feldman HI, Xie D, Zhang X, Mifflin T, Waikar SS, Sabbisetti VS, Bonventre JV, Coresh J, Nelson RG, Kimmel PL, Kusek JW, Rahman M, Schelling JR, Vasan RS, Liu KD. Urine Kidney Injury Biomarkers and Risks of Cardiovascular Disease Events and All-Cause Death: The CRIC Study. Clin J Am Soc Nephrol. 2017 May 08; 12(5):761-771. View in PubMed
  5. Park M, Shlipak MG, Thiessen-Philbrook H, Garg AX, Koyner JL, Coca SG, Parikh CR. Association of Peak Changes in Plasma Cystatin C and Creatinine With Death After Cardiac Operations. Ann Thorac Surg. 2016 Apr; 101(4):1395-401. View in PubMed
  6. Park M, Shlipak MG, Vittinghoff E, Katz R, Siscovick D, Sarnak M, Lima JA, Hsu CY, Peralta CA. Associations of kidney injury markers with subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Clin Nephrol. 2015 Dec; 84(6):358-63. View in PubMed
  7. Bansal N, Carpenter MA, Weiner DE, Levey AS, Pfeffer M, Kusek JW, Cai J, Hunsicker LG, Park M, Bennett M, Liu KD, Hsu CY. Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. J Am Soc Nephrol. 2016 Jul; 27(7):2109-21. View in PubMed
  8. Park M, Kulkarni A, Beatty A, Ganz P, Regan M, Vittinghoff E, Whooley M. Soluble endothelial cell selective adhesion molecule and cardiovascular outcomes in patients with stable coronary disease: A report from the Heart and Soul Study. Atherosclerosis. 2015 Dec; 243(2):546-52. View in PubMed
  9. Wu EH, Wojciechowski D, Chandran S, Yeh BM, Park M, Westphalen A, Wang ZJ. Prevalence of abdominal aortic calcifications in older living renal donors and its effect on graft function and histology. Transpl Int. 2015 Oct; 28(10):1172-8. View in PubMed
  10. Park M. Islands in the stream: the risk of kidney disease from cardiovascular disease. Am J Kidney Dis. 2015 May; 65(5):647-9. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Meyeon Park, MD, MAS, FASN
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.